exenatide once weekly + insulin detemir

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Type 2 Diabetes Mellitus

Conditions

Type 2 Diabetes Mellitus

Trial Timeline

Oct 1, 2009 โ†’ Dec 1, 2011

About exenatide once weekly + insulin detemir

exenatide once weekly + insulin detemir is a phase 3 stage product being developed by Eli Lilly for Type 2 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT01003184. Target conditions include Type 2 Diabetes Mellitus.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01003184Phase 3Completed